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Spironolactone produces antiacne effects and has recently 
been shown to inhibit 5a-dihydrotestosterone (5a-DHT) 
receptors in human sebaceous glands. We applied spirono-
lactone alone and combined with testosterone and 5a-DHT 
to investigate its effects on'the proliferation of human sebo-
cyte cultures derived from facial skin. Secondary human fa-
cial sebocytes in 96-well culture plates were treated for 10 d 
by a single or combined application of testosterone (10- 8 -
10-5 M), 5a-DHT (10-8 - 10-5 M), and spironolactone 
(10- 12 _10- 7 M) in serum-free basal medium. Cell prolifera-
tion was assessed in six wells using a fluorometric assay. Tes-
tosterone and 5a-DHT significantly stimulated sebocyte 
Spironolactone is an aldosterone antagonist that has been clinically used as an antihypertensive and diuretic drug. The fact that gynecomastia is a common side effect of this compound reflects its antiandrogenic property [1 ,2]. Spir-onolactone has also been successfully used for treatment of 
acne [3,4]' hirsutism [5], and androgenic alopecia [6] . The following 
mechanisms have been thought to explain its action: 1) interference 
with steroid synthesis by blockage of cytochrome P4S0 enzymes in 
the testes and adrenal glands [7,8]; 2) reduction of Sa-reductase 
activity [9]; and 3) peripheral action by a competitive decrease in 
5a-dihydrotestosterone (5a-DHT) activity at the receptor level, as 
has been demonstrated both in experimental animals and in humans 
[10,11]. 
Our aim was to better elucidate the effects of spironolactone on 
the sebaceous glands at the cellular level by investigating its direct 
influence on the proliferation of cultured human facial sebocytes il1 
vitro as weIJ as its possible modification of testosterone and Sa-DHT 
activity in this connection. 
MATERIALS AND METHODS 
Human Sebocyte Cultures Human sebaceous glands were iso-
lated from facial skin and seeded on monolayer 3T3 cells, as previ-
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Abbreviations: 
AFU: absolute fluorescence units 
5a-DHT: Sa-dihydrotcstostcrone 
DMSO: dimethyl sulfoxide 
KBM: se rum-free keratinocyte basal medium 
MUH: 4-methylumbclliferyl hcptanoate 
proliferation in a dose-dependent manner, the effect being 
strongest with 5a-DHT. Spironolactone, on the other hand, 
caused a dose-dependent inhibition (25% and 50% at 10-9 
and 10-7 M, respectively). Combined treatment of human 
facial sebocytes with spironolactone and testosterone or 50'-
DHT resulted in a lower proliferation than with androgens 
alone. The fact that spironolactone directly and dose depen-
dently inhibits the proliferation of cultured human facial 
sebocytes and acts antagonistically to testosterone and 50'-
DHT at the cellular level is indicative of a receptor-mediated 
effect. ] Invest DermatoI100:660- 662, 1993 
ously described [12] . Primary sebocyte cultures were derived from 
the periphery of the gland lobules and were maintained to con-
fluence before subcultivation. All experiments were performed 
using secondary sebocyte cu ltures, which have been demonstrated 
to consist of ceIJs undergoing sebocytic differentiation [13,14] . 
Treatment with Testosterone, Sa-DHT, and Spironolactone 
Human sebocytes were seeded in 96-well culture plates (Falcon, 
Jersey, NJ) at a concentration of 104 cells/well and were left to 
attach for 2 d at 37 °C with 5% CO2 in culture medium consisting 
of Dulbecco's modified Eagle's medium and Ham's F12 medium 
(1: 1) (Gibco, Berlin, Germany) supplemented with 8% fetal calf 
serum (Seromed, Berlin, Germany), 2% human serum, 10 ng/ml 
epidermal growth factor (Sigma, Deisenhofen, Germany), 10-9 M 
cholera toxin (Calbiochem, Frankfurt, Germany), 3.4 mM L-gluta-
mine, 100 IU/ml penicillin, and 100 Ilg/ml streptomycin (all from 
Seromed). The medium was then aspirated, and serum-free kerati-
nocyte basal medium (KBM) (Clonetics, San Diego, CA) without 
additives supplemented with testosterone (10- 8 -10- 5 M) (Sigma), 
5a-DHT (10- 8 - 1O-s M) (Sigma), or spironolactone (10- 12 -
10-7 M) (Searle Yakuhin, Osaka, Japan) or their combination was 
added to six wells at each concentration. The compounds were 
added to the medium as a 0.2% dimethyl sulfoxide (DMSO) 
(Merck, Darmstadt, Germany) solution. KBM with 0.2% DMSO 
was concomitantly added to another six wells serving as controls. 
The plates were incubated at 3rc for 10 d before evaluation. KBM 
with and without compounds was changed every 2 d. 
Cell Proliferation Cell numbers of untreated human sebocytes 
in 96-well culture plates were assessed over 9 d by counting single-
cell suspensions in Neubauer chambers and were compared with the 
absolute fluorescence units (AFU) of parallel wells obtained using 
the 4-methylumbelliferyl heptanoate (MUH) - fluorescence assa 
[15,16] . This assay is based on the hydrolysis of the fluorogenic 
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Figure 1. Comparison of cellnumbcrs of proliferating human sebocytes in 
culture (open circles) and of AFU in parallel cultures obtained using the 
MUH-f1uorescence assay (closed circles). Valucs arc mcan ± SO of six wells 
and are presentcd as percent of cell numbcr and percent of AFU on the day of 
assessment compared with day o. 
substrate MUH by esterases of proliferating cells. Briefly, a stock 
solution of 10 mg/ml MUH (Serva, Heidelberg, Germany) was 
prepared in DMSO and kept frozen at - 20 0 C until use. On the day 
of assessment, KBM was removed, and the cells were washed twice 
with phosphate-buffered saline without Ca++ and Mg++ (pH 7.2) 
(Seromed). The MUH stock solution was diluted in phosphate-buf-
fered saline up to 100 ,ug/ml, and 100,ul of the final solutIOn was 
added to each well. The plates were then incubated for 30 min at 
3rC and read automatically on a Titertek Fluoroscan II (Flow, 
Meckenheim, Germany). The MUH-fluorescence assay was used to 
assess the effects of androgens and spironolactone on sebocyte prolif-
eration. The results are given as AFU using 355-nm excitation and 
460-nm emission filters . 
Statistical Evaluation Each value represents the mean of six 
wells ± 1 SD. Statistical significance was assessed by Student t test. 
Mean differences were considered significant at p < 0.05. 
RESULTS 
Sebocyte proliferation was highly correlated with the results ob-
tained using the MUH-fluorescence assay (Fig 1). Spironolactone 
inhibited the proliferation of cultured human sebocytes derived 
from sebaceous glands of the facial skin in a significant and dose-de-
pendent manner. The inhibitory effect was 25% at .1 0- 9 M and 50% 
at 10-7 M (10- 9 , 10- 8 , and 10-7 M; P < 0.01) (Fig 2). 
Testosterone stimulated the proliferation of cultured human fa-
cial sebocytes, the effect being 25% at 10- 7 _10- 6 M and 50% at 
10- 5 M (10- 6 and 10- 5 M; p < 0.01) (Fig 3a). 5a-DHT markedly 
enhanced the proliferation of cultured human facial sebocytes in a 
dose-dependent manner: 25% at 10-8 M and 50% at 10- 7 M (for all 
concentrations tested p < 0.01) (Fig 3b). 
Spironolactone significantly inhibited the stimulatory effect of 
testosterone on the proliferation of cultured human facial sebocytes 
in vitro. Inhibitory effects were 3 - 5% at 10- 9 M, 14 - 22% at 
10-8 M, and 22 - 36% at 10-7 M of spironolactone when added 
together with different testosterone concentrations to human facial 
sebocyte cultures (spironolactone 10- 8 M plus testosterone 10-8 M, 
P < 0.05; spironolactone 10-7 M plus testosterone 10-7, 10- 6, and 
10-5 M, P < 0.05; spironolactone 10- 7 M plus testosterone 
10-8 M, P < 0.01) (Fig 3a). 
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Figure 2. Effect of spironolactone on the proliferation of cultu red human 
sebocytes derived from sebaceous glands of facial skin, as assessed by the 
MUH-fluorescence assay. Values are mean ± SO of six wells and are 
presented as percent of controls (Cont.) . •• p < 0.01 , compared with con-
trols. 
In a similar way, the stimulatory effect of 5a-DHT on the prolif-
eration of cultured human facial sebocytes was dose dependently 
reduced by spironolactone. Inhibitory effects were 14 - 20% at 
10- 9 M, 19 - 30% at 10-8 M , and 22 - 45% at 10-7 M of spirono-
lactone when added together with different 5a-DHT concentra-
tions to the proliferating cells (spironolactone 10-9 M plus 5a-
DHT 10- 8 M, P < 0.05; spironolactone 10-8 M plus all 5a-DHT 
concentrations tested, p < 0.05; spironolactone 10-7 M plus 5a-
DHT 10-8 M, P < 0.05; spironolactone 10-7 M plus 5a-DHT 
10- 7 , 10-6 , and 10- 5 M, P < 0.01) (Fig 3b). 
DISCUSSION 
Androgens cause hyperactivity of sebaceous glands, with increased 
sebum secretion [17) . The resulting seborrhea promotes the forma-
tion of acne lesions [18] . The major circulating androgen, testoster-
one, is intracellularly converted in the skin to 5a-DHT by the 
enzyme Sa-reductase [19,20] . The androgenic effect of 5a-DHT is 
probably mediated by its binding to androgen receptors. Androgen 
receptors have been demonstrated in human sebaceous glands 
[21,22]. Therefore, hypersecretion of androgens and increased tes-
tosterone metabolism to 5a-DHT are closely correlated to the 
pathogenesis of acne [23 - 27) . 
In this study, the proliferation of cultured human facial sebocytes 
was shown to be significantly stimulated by testosterone and 5a-
DHT but markedly inhibited in a dose-dependent manner by.s~l­
ronolactone and testosterone or 5a-DHT simultaneously admlllls-
teredo These observations indicate that spironolactone antagoni~es 
testosterone and 5a-DHT activity, inhibiting their stimulatory 11~­
fluence on the proliferation of human facial sebocytes in vitro. EVI-
dence suggests that such an effect may be due to inhibition of Sa-re-
ductase reduction of testosterone to 5a-DHT [9] and r artial or. t?tal 
blockage of Sa-DHT binding to its receptor [10,11 . In addJt1on, 
increasing doses of spironolactone produced a corresponding prolif-
eration inhibition indicative of a receptor-monitored effect. Thus, 
spironolactone may antagonize 5a-DHT by binding to its receptor 
or by modifying the structure of its receptor. It seems likely that the 
ligand - receptor interaction is disturbed. 
An inhibitory effect of spironolactone on 5a-DHT - st.im.ula~ed 
proliferation of human sebocytes derived from femoral skill III vitro 
was previously observed by our study group [28]; however, sebo-
cytes may respond differently to androgens, depending on the loca-
tion of the sebaceous glands [29]. The results of our study also 
confirm the inhibitory effect of spironolactone on testosterone- and 
5a-DHT -stimulated proliferation of sebocytes denved from faCial 
skin. 
In conclusion, spironolactone may produce its antiacne effect by 
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Figure 3. Effect of spironolactone on the stimulatory influence of (aJ testos-
terone and (b) 5a-DHT on the proliferation of cultured human sebocytes 
derived from sebaceous glands of facial skin, as assessed by the MUH-fluore-
scence assay. Values are mean ± so of six wells and are presented as percent 
of controls .• p < 0.05, •• P < 0.01, compared with testosterone- and 5a-
DHT - treated controls, respectively. 
directly inhibiting the proliferation of human sebocytes and by act-
ing antagonistically on the StimulatIOn of the sebaceous gland by 
testosterone and, above all, by Sa-DHT at the cellular level. Both 
effects seem to be receptor mediated. 
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